Literature DB >> 17277134

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.

Alja J Stel1, Bram Ten Cate, Susan Jacobs, Jan Willem Kok, Diana C J Spierings, Monica Dondorff, Wijnand Helfrich, Hanneke C Kluin-Nelemans, Lou F M H de Leij, Sebo Withoff, Bart Jan Kroesen.   

Abstract

Ab binding to CD20 has been shown to induce apoptosis in B cells. In this study, we demonstrate that rituximab sensitizes lymphoma B cells to Fas-induced apoptosis in a caspase-8-dependent manner. To elucidate the mechanism by which Rituximab affects Fas-mediated cell death, we investigated rituximab-induced signaling and apoptosis pathways. Rituximab-induced apoptosis involved the death receptor pathway and proceeded in a caspase-8-dependent manner. Ectopic overexpression of FLIP (the physiological inhibitor of the death receptor pathway) or application of zIETD-fmk (specific inhibitor of caspase-8, the initiator-caspase of the death receptor pathway) both specifically reduced rituximab-induced apoptosis in Ramos B cells. Blocking the death receptor ligands Fas ligand or TRAIL, using neutralizing Abs, did not inhibit apoptosis, implying that a direct death receptor/ligand interaction is not involved in CD20-mediated cell death. Instead, we hypothesized that rituximab-induced apoptosis involves membrane clustering of Fas molecules that leads to formation of the death-inducing signaling complex (DISC) and downstream activation of the death receptor pathway. Indeed, Fas coimmune precipitation experiments showed that, upon CD20-cross-linking, Fas-associated death domain protein (FADD) and caspase-8 were recruited into the DISC. Additionally, rituximab induced CD20 and Fas translocation to raft-like domains on the cell surface. Further analysis revealed that, upon stimulation with rituximab, Fas, caspase-8, and FADD were found in sucrose-gradient raft fractions together with CD20. In conclusion, in this study, we present evidence for the involvement of the death receptor pathway in rituximab-induced apoptosis of Ramos B cells with concomitant sensitization of these cells to Fas-mediated apoptosis via Fas multimerization and recruitment of caspase-8 and FADD to the DISC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277134     DOI: 10.4049/jimmunol.178.4.2287

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 2.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-11-07       Impact factor: 5.922

Review 3.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

Review 4.  CD95-mediated cell signaling in cancer: mutations and post-translational modulations.

Authors:  Sébastien Tauzin; Laure Debure; Jean-François Moreau; Patrick Legembre
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

5.  Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.

Authors:  Mary C Clark; Mabel Pang; Daniel K Hsu; Fu-Tong Liu; Sven de Vos; Randy D Gascoyne; Jonathan Said; Linda G Baum
Journal:  Blood       Date:  2012-10-12       Impact factor: 22.113

6.  Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Authors:  Mattias Magnusson; Mikael Brisslert; Kiandoht Zendjanchi; Magnus Lindh; Maria I Bokarewa
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

7.  Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein.

Authors:  Zuzana Berkova; Shu Wang; Jillian F Wise; Hoyoung Maeng; Yuan Ji; Felipe Samaniego
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

8.  Importance of the difference in surface pressures of the cell membrane in doxorubicin resistant cells that do not express Pgp and ABCG2.

Authors:  Charlotte Bell; Claire Hill; Christopher Burton; Adam Blanchard; Freya Shephard; Cyril Rauch
Journal:  Cell Biochem Biophys       Date:  2013-07       Impact factor: 2.194

Review 9.  Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms.

Authors:  Wasif Riaz; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

10.  Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.

Authors:  Jillian F Wise; Zuzana Berkova; Rohit Mathur; Haifeng Zhu; Frank K Braun; Rong-Hua Tao; Anita L Sabichi; Xue Ao; Hoyoung Maeng; Felipe Samaniego
Journal:  Blood       Date:  2013-04-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.